ClinicalTrials.gg
CompletedNCT05417854ULTRAUpdated Oct 12, 2023

Ultrasound Treatment for Rheumatoid Arthritis Study [ULTRA Study]

An interventional study of Splenic Ultrasound in Rheumatoid Arthritis, sponsored by SecondWave Systems Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by SecondWave Systems Inc. · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 121 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Enrollment
695th of 771
14 · median 120
Started
2022
with 25 others
No phase
164 of 975
18 open now
Registered
866th of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 695th largest by enrollment of the 771 interventional ones that give a count, is one of 26 that started in 2022, is one of 164 with no phase, and was the 866th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

The research objective is to assess efficacy of spleen ultrasound stimulation in the treatment of rheumatoid arthritis (RA) in a pilot study.

Specific Aims:

  • Measure RA disease activity and clinical metrics during and after an 8-week course of spleen-directed daily ultrasound treatments.
  • Measure molecular correlates, including Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), cortisol and cytokine levels, of rheumatoid arthritis disease activity during spleen-directed daily ultrasound treatments.
Read the detailed description

Ultrasound is widely used in human medicine because it is safe, non-invasive, and painless. The same kind of ultrasound that is used for imaging (for example, to visualize babies in utero) may be able to treat inflammatory diseases including Rheumatoid Arthritis.

Multiple studies in animals with hyper-inflammation conditions (e.g., inflammatory arthritis and sepsis/lipopolysaccharide [LPS] injections) and recent human studies (e.g., for the treatment of joint inflammation in Rheumatoid Arthritis) have shown that ultrasound applied to the spleen can suppress blood/genetic markers of inflammation.

This study will employ investigational ultrasound devices produced by SecondWave Systems called the MINI ultrasound system.

This is a pilot single-arm treatment trial in which up to 15 study participants will receive noninvasive splenic-ultrasound therapy over eight weeks (five daily stimulation sessions per week). Clinical outcomes will be compared from baseline to end of the 8-week treatment period. Investigational splenic-ultrasound therapy will be delivered with the SecondWave MINI ultrasound system. The objective of the study is to assess the safety and potential efficacy for the MINI system for treatment of Rheumatoid Arthritis.

For ultrasound stimulation, a small wearable ultrasound device is positioned on the upper left abdomen area over the ribs. Study personnel will use an ultrasound imaging device to locate the spleen and to position the wearable MINI device in a proper location around the ribs area. Daily stimulation consists of an approximately 18-minute period for application of ultrasound to the spleen. Collection of clinical outcome data, patient-reported assessments, and blood draws collected at the 5 study visits to assess biomarkers of inflammation will be performed in each participant throughout the study.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ages 18 and above
  2. Must carry a diagnosis of rheumatoid arthritis, as defined by the American College of Rheumatology in 2010: (https://www.rheumatology.org/Portals/0/Files/2010_revised_criteria_classification_ra.pdf)

    • Classification as "definite RA" is based on the confirmed presence of synovial thickening in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints (score range 0-5), serologic abnormality (score range 0-3), elevated acute-phase response (score range 0-1), and symptom duration (2 levels; range 0-1)
  3. Exhibiting symptoms or signs of inadequate inflammatory disease control according to one of two measures:

    1. Multidimensional HAQ score of greater than 0.3
    2. DAS-28-CRP greater than 3.2 (http://www.phusewiki.org/wiki/index.php?title=Disease_Activity_Score_-_CRP_(DAS-CRP)
  4. Candidate participant's rheumatoid arthritis medical therapy should be stable for two weeks leading up to the study. Moreover, participants must be willing to maintain their current medication regimen throughout the study enrollment period (in adjunct to the additional ultrasound treatment)

Exclusion criteria

Exclusion Criteria:

  1. Active bacterial or viral infection
  2. Pregnant women or those trying to become pregnant
  3. Receiving active chemotherapy or immunotherapy to treat within 30 days prior to enrollment
  4. Having received Rituximab monoclonal antibody medication within 30 days prior to enrollment
  5. Presence of an implanted device
  6. Asplenia
  7. Splenomegaly
  8. Ascites
  9. Recent abdominal surgery
  10. Currently participating in an drug or device study
  11. Open wound/sores near stimulation sites
  12. Inability to perform minimal daily self-cares associated with feeding/dressing, according to HAQ
  13. Any other clinical reasons deemed by the investigators of the study in which the patient would not be an appropriate candidate for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Ultrasound Group

    Device: Splenic Ultrasound

Interventions

  • DeviceSplenic Ultrasound

    Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.

    Also known as: SecondWave Systems investigational MINI device

06

What researchers measure

Primary outcomes

  1. Within-arm change in the Disease Activity Score (DAS-28-CRP) from baseline to the completion of an up-to 8-week treatment period.

    A decrease in Disease Activity Score indicates an improved outcome.

    Time frame: 8 weeks

Other outcomes

  1. Within-arm change of serum c-reactive protein (CRP) concentration.

    Time frame: 8 weeks

  2. Within-arm change of serum erythrocyte sedimentation rate (ESR).

    Time frame: 8 weeks

  3. Within-arm change of serum cortisol levels.

    Time frame: 8 weeks

  4. Within-arm change of serum Tumor Necrosis Factor (TNFa) concentration.

    Time frame: 8 weeks

  5. Within-arm change of serum Interleukin-1 beta (IL-1beta) concentration.

    Time frame: 8 weeks

  6. Within-arm change of serum Interleukin-6 (IL-6) concentration.

    Time frame: 8 weeks

  7. Within-arm change of serum Interleukin-6 (IL-8) concentration.

    Time frame: 8 weeks

  8. Within-arm change of serum Interferon gamma (IFN-gamma) concentration.

    Time frame: 8 weeks

  9. Within-arm change on the Multidimensional Health Assessment Questionnaire (HAQ).

    A decreased score on the HAQ indicates an improved outcome.

    Time frame: 8 weeks

  10. Within-arm change on the EQ-5D health questionnaire.

    A decreased score on questions from the EQ-5D indicates an improved outcome.

    Time frame: 8 weeks

  11. Exit interview questions.

    These questions ask the participant about whether they feel that they have benefited from the investigational treatment, whether they would recommend the investigational treatment to others, and the comfort level of the investigational treatment.

    Time frame: End of study participation

07

Study locations

2 sites
  • University of Minnesota - Phillips-Wangensteen Building
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota Health Clinics and Surgery Center
    Minneapolis, Minnesota 55455, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jul 2023, 12 months.

Of 56 industry-sponsored interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 92. This study's 12 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2022
First posted
Jun 14, 2022
StartActual
Jun 29, 2022
Primary completionActual
Jul 19, 2023
CompletionActual
Sep 25, 2023
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05417854
Lead sponsor
SecondWave Systems Inc.
Collaborators
University of Minnesota, DARPA (United States Department of Defense)
Responsible party
Sponsor
First posted
Jun 14, 2022
Start date
Jun 29, 2022
Primary completion
Jul 19, 2023
Completion
Sep 25, 2023
Last update
Oct 12, 2023

Study contacts

Erik Peterson, M.D.
principal investigator · University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion